
Pulmonary/ Respiratory Drug Delivery
Description
Pulmonary/ Respiratory Drug Delivery
Global Pulmonary / Respiratory Drug Delivery Market to Reach $66 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Pulmonary / Respiratory Drug Delivery estimated at US$47.6 Billion in the year 2020, is projected to reach a revised size of US$66 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Metered Dose Inhalers, one of the segments analyzed in the report, is projected to record a 4.3% CAGR and reach US$28.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dry Powder Inhalers segment is readjusted to a revised 5.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $13.8 Billion, While China is Forecast to Grow at 4.4% CAGR
The Pulmonary / Respiratory Drug Delivery market in the U.S. is estimated at US$13.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.6 Billion by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.
Nebulizers Segment to Record 4.7% CAGR
In the global Nebulizers segment, USA, Canada, Japan, China and Europe will drive the 4.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$9.8 Billion in the year 2020 will reach a projected size of US$13.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Global Pulmonary / Respiratory Drug Delivery Market to Reach $66 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Pulmonary / Respiratory Drug Delivery estimated at US$47.6 Billion in the year 2020, is projected to reach a revised size of US$66 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Metered Dose Inhalers, one of the segments analyzed in the report, is projected to record a 4.3% CAGR and reach US$28.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dry Powder Inhalers segment is readjusted to a revised 5.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $13.8 Billion, While China is Forecast to Grow at 4.4% CAGR
The Pulmonary / Respiratory Drug Delivery market in the U.S. is estimated at US$13.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.6 Billion by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.
Nebulizers Segment to Record 4.7% CAGR
In the global Nebulizers segment, USA, Canada, Japan, China and Europe will drive the 4.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$9.8 Billion in the year 2020 will reach a projected size of US$13.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 42 Featured) -
- 3M Company
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG
- Omron Corporation
- Sunovion Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
194 Pages
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Pulmonary/ Respiratory Drug Delivery – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Pulmonary/ Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
- TABLE 4: World Recent Past, Current & Future Analysis for Metered dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Metered dose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Metered dose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 7: World Recent Past, Current & Future Analysis for Dry Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Dry Powder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Dry Powder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 10: World Recent Past, Current & Future Analysis for Nebulizer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 11: World Historic Review for Nebulizer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 12: World 15-Year Perspective for Nebulizer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 13: World Recent Past, Current & Future Analysis for Accessories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 14: World Historic Review for Accessories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 15: World 15-Year Perspective for Accessories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 16: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 17: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 18: World 15-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 19: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 20: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 21: World 15-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 22: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 23: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 24: World 15-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 27: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 28: World Pulmonary/ Respiratory Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
- III. MARKET ANALYSIS
- UNITED STATES
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 30: USA Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 31: USA 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 32: USA Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 33: USA Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 34: USA 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 36: Canada Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 38: Canada Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 39: Canada Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 40: Canada 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- JAPAN
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 42: Japan Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 43: Japan 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 44: Japan Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 45: Japan Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 46: Japan 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- CHINA
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 48: China Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 49: China 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 50: China Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 51: China Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 52: China 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- EUROPE
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 54: Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 55: Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
- TABLE 56: Europe Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 57: Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 58: Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 59: Europe Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 60: Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 61: Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- FRANCE
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 63: France Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 64: France 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 65: France Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 66: France Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 67: France 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- GERMANY
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 69: Germany Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 70: Germany 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 71: Germany Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 72: Germany Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 73: Germany 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 75: Italy Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 76: Italy 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 77: Italy Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 78: Italy Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 79: Italy 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- UNITED KINGDOM
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 81: UK Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 82: UK 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 83: UK Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 84: UK Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 85: UK 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- REST OF EUROPE
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 87: Rest of Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 88: Rest of Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 91: Rest of Europe 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- ASIA-PACIFIC
- Pulmonary/ Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 93: Asia-Pacific Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 94: Asia-Pacific 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 97: Asia-Pacific 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- REST OF WORLD
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 99: Rest of World Historic Review for Pulmonary/ Respiratory Drug Delivery by Device Type - Metered dose, Dry Powder, Nebulizer and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 100: Rest of World 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Device Type - Percentage Breakdown of Value Sales for Metered dose, Dry Powder, Nebulizer and Accessories for the Years 2012, 2021 & 2027
- TABLE 101: Rest of World Recent Past, Current & Future Analysis for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 102: Rest of World Historic Review for Pulmonary/ Respiratory Drug Delivery by Application - Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 103: Rest of World 15-Year Perspective for Pulmonary/ Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis and Other Applications for the Years 2012, 2021 & 2027
- IV. COMPETITION
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.